Anticoagulants Market Revenue Growth Defined by Heightened Product Innovation : Fact.MR

According to a recently published Fact.MR report, the global anticoagulants market is expected to reach US$ 30 Bn by 2021-end, with an expected value CAGR of 8.04% across the forthcoming decade. Furthermore, the market is expected to close in at US$ 65 Bn by the end of the 2021-2031 assessment period.

Historical performance of the market establishes that the market registered a steady CAGR of 5% from 2016 to 2020. Amidst the COVID-19 pandemic, demand for anticoagulants expanded significantly, as patients experienced high levels of post-COVID complications, majorly manifesting into cardiac anomalies.

For critical insights on this market, request for More Info - https://www.factmr.com/connectus/sample?flag=S&rep_id=4335

Key Segments Covered

Drug Class
Factor X Inhibitor (NOAC/DOAC) Anticoagulants
Heparin Anticoagulants
Direct Thrombin Inhibitor Anticoagulants
Vitamin K Antagonist Anticoagulants

Indication
Anticoagulants for Deep Vein Thrombosis
Anticoagulants for Pulmonary Embolism
Anticoagulants for Atrial Fibrillation & Heart Attack
Anticoagulants for Other Indications

Route of Administration
Oral Anticoagulants
Injectable Anticoagulants

Distribution Channel
Anticoagulants Sales via Hospital Pharmacies
Anticoagulants Sales via Retail Pharmacies
Anticoagulants Sales via Online Pharmacies

Request more information about Report Methodology - https://www.factmr.com/connectus/sample?flag=RM&rep_id=4335

Key Takeaways from Anticoagulants Market Study

Global market for anticoagulants to surge more than 2x until 2031
By route of administration, oral anticoagulants captured around 54% revenue in 2020
Factor-X inhibitors (NOAC/DOAC) anticoagulants accounted for over 50% of global demand in 2019
By distribution channel, hospitals remain primary anticoagulants disbursers, clocking 49.5% of total sales
U.S to be an attractive market, experiencing a CAGR of 7.5% through 2031
Japan to account for over 2 out of 5 anticoagulants sales in East Asia
China is expected to increase at the fastest rate, registering a growth rate of 8% through 2031

Competitive Landscape

With several prominent players, the anticoagulants industry is competitive and fragmented. Players in the anticoagulants business are stepping forward to shoulder the financial burden of individuals through patient-assistance programmes as a strategy to expand anticoagulant exposure.

For example, the Bristol-Myers Squibb Foundation provides financial assistance to patients in order for them to get medications. The programme, however, exclusively assists US citizens who are not covered by a privately or publicly traded firm.

The PRADAXA savings card, which is provided by Boehringer Ingelheim, allows patients to purchase drugs at a discounted cost. A rise in the number of manufacturers using financial strategies is projected to boost medicine consumption throughout the forecast period.

For in-depth competitive analysis, Now - https://www.factmr.com/checkout/4335

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email : sales@factmr.com
Website : https://www.factmr.com

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.